All studies
Ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humansInterventional
A study to Evaluate AB308 in Combination with AB122 in Participants with Advanced Malignancies (ARC-12)
At a glance
Status
Ongoing, recruiting
Phase
Human Pharmacology (Phase I)- First administration to humans
Sponsor
Arcus Biosciences Inc.
Enrolment target
18
Start
10 May 2024
Multiple MyelomaDiffuse large B cell lymphoma (DLBCL)Esophageal CancerGastroesophageal Junction AdenocarcinomaMelanomaAdvanced Solid TumorGastrointestinal (GI) cancerHematological (heme) cancerGynecological (Gyn) cancerNon-small cell lung cancer (NSCLC)Non-Hodgkin LymphomaGastric CancerCervical Cancer
Who may be eligible?
Age 18 Years to any · Sex: All
Locations (2)
- —Spain
- —Poland
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.